EX-99.1 2 d619899dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

UNITED STATES BANKRUPTCY COURT

FOR THE DISTRICT OF DELAWARE

 

In re: Orexigen Therapeutics, Inc.

Debtor

   

Case No. 18-10518 (KG)

Reporting Period: August 1, 2018 - August 31, 2018

MONTHLY OPERATING REPORT

File with Court and submit copy to United States Trustee within 20 days after end of month.

Submit copy of report to any official committee appointed in the case.

 

REQUIRED DOCUMENTS

    Form No.      Document
Attached		    Explanation
Attached		      Affidavit/Supplement
Attached		  

Schedule of Cash Receipts and Disbursements

      MOR-1      X      

Schedule of Disbursements by Debtor Entity

      MOR-la      X      

Schedule of Debtor Bank Account Balances

      MOR-lb      X      

Schedule of Professional Fees and Expenses Paid

      MOR-lc      X      

Copies of bank statements

               Certification Attached  

Cash disbursements journals

               Certification Attached  

Bank reconciliation

               Certification Attached  

Statement of Operations

      MOR-2      X      

Balance Sheet

      MOR-3      X      

Status of Postpetition Taxes

               Certification Attached  

Copies of IRS Form 6123 or payment receipt

               Certification Attached  

Copies of tax returns filed during reporting period

               Certification Attached  

Summary of Unpaid Postpetition Debts

            

Summary of Unpaid Post Petition Accounts Payables

      MOR-4      X      

Accounts Receivable Aging

      MOR-5      X      

Debtor Questionnaire

      MOR-5      X      

I declare under penalty of perjury (28 U.S.C. Section 1746) that this report and the attached documents are true and correct to the best of my knowledge and belief.

 

/s/ Thomas P. Lynch     27 SEPT 2018
Signature of Authorized Individual*     Date
/s/ Thomas P. Lynch     Chief Administrative Officer and General Counsel
Printed Name of Authorized Individual     Title of Authorized Individual

 

*

Authorized individual must be an officer, director or shareholder if debtor is a corporation; a partner if debtor is a partnership; a manager or member if debtor is a limited liability company.

Notes:

The last four digits of Debtor’s federal tax identification number are (8822). The Debtor’s mailing address for purposes of this chapter 11 case is 3344 North Torrey Pines Court, Suite 200, La Jolla, CA, 92037.

UNITED STATES BANKRUPTCY COURT

FOR THE DISTRICT OF DELAWARE

 

In re: Orexigen Therapeutics, Inc.

Debtor

   

Case No. 18-10518 (KG)

Reporting Period: August 1, 2018 - August 31, 2018

CERTIFICATION REGARDING POST-PETITION BANK ACCOUNT

RECONCILIATIONS, CASH DISBURSEMENT JOURNALS AND

COMPLIANCE AND PAYMENT OF POST-PETITION TAXES

I, Thomas Lynch, Chief Administrative Officer & General Counsel, of Orexigen Therapeutics, Inc. (the “Debtor”) hereby certify the following:

1. Attached to MOR-1 is a listing of the Debtor’s bank accounts, by account number, and the opening and closing balances. These accounts are reconciled monthly in accordance with the Debtor’s ordinary course accounting practices and are available to the United States Trustee upon request.

2. Cash disbursement journals are maintained in accordance with the Debtor’s ordinary course accounting practices and are available to the United States Trustee upon request.

3. To the best of my knowledge and belief, the Debtor is current on all post-petition taxes, and no post-petition tax amounts are past due.

 

/s/ Thomas P. Lynch     27 SEPT 2018
Thomas Lynch     Date
Chief Administrative Officer & General Counsel    

UNITED STATES BANKRUPTCY COURT

FOR THE DISTRICT OF DELAWARE

 

In re: Orexigen Therapeutics, Inc.

Debtor

   

Case No. 18-10518 (KG)

Reporting Period: August 1, 2018 - August 31, 2018

Notes to Monthly Operating Report

Debtor in Possession Financial Statements

The financial statements and supplemental information presented in this Monthly Operating Report (“MOR”) have been prepared using the Debtor’s books and records solely to comply with the monthly reporting requirements under the United States Bankruptcy Code and those of the United States Trustee for Region Three.

The financial statements and supplemental information presented herein are unaudited, preliminary in nature, and may not comply with generally accepted accounting principles in the United States of America (“U.S. GAAP”) in all material respects. These preliminary unaudited financial statements and other information represent the Debtor’s good faith attempt to comply with the requirements of the United States Bankruptcy Code and those of the United States Trustee using the resources available. This information is limited in scope to the requirements of this report.

These preliminary unaudited financial statements have not been subject to procedures that would typically be applied to financial information presented in accordance with U.S. GAAP, and upon application of such procedures, the Debtor believes that the financial information could be subject to changes, which could be material. Certain totals may not sum due to rounding.

All related tax implications are not currently reflected in the preliminary unaudited financial statements herein. The financial impact of potential tax and other adjustments on the accompanying preliminary unaudited financial statements cannot be determined at this time.

There may be adjustments to the opening balance sheet as of March 12, 2018 that will impact these accompanying preliminary unaudited financial statements. ASC 805 permits a one-year measurement period in which the opening balance sheet can be adjusted if additional information becomes available.

Liabilities Subject to Compromise

As a result of the commencement of the Debtor’s chapter 11 case, the payment of certain prepetition indebtedness of the Debtor is subject to compromise or other treatment under a plan of reorganization.

Reorganization Items

ASC 852 requires expenses and income directly associated with the Debtor’s chapter 11 cases to be reported separately in the income statement as reorganization items. Reorganization items include expenses related to legal advisory and representation services, and other professional consulting and advisory services. Reorganization costs also include adjustment to record debt at the estimated amount of the claim and an estimate of the loss on sale of assets which is pending a valuation.

Litigation

The Debtor is subject to lawsuits and claims that arise out of its operations in the normal course of business.

Prior to the petition date, the Debtor was the defendant to various legal proceedings, described in detail in the most recent publicly filed financial statements, which are stayed during the course of the chapter 11 bankruptcy proceedings.

There are uncertainties inherent in any litigation and appeal and the Debtor cannot predict the outcome. At this time the Debtor is unable to estimate possible losses or ranges of losses that may result from such legal proceedings described in detail in the most recent publicly filed financial statements, and it has not accrued any amounts in connection with such legal proceedings in the financial statements herein, other than attorney’s fees accrued prior to the petition date.

Sale Transaction

On April 23, 2018, the Debtor entered into an asset purchase agreement with Nalpropion Pharmaceuticals, Inc. (the “Buyer”) for the sale of substantially all of its assets through section 363 of the Bankruptcy Code. This transaction was subsequently approved by the Bankruptcy Court on June 28, 2018. On July 27, 2018, the Debtor closed the sale and transferred substantially all of its assets to the Buyer. As part of the sale, the Debtor entered into a transition services agreement for the post-closing period through the effective date of a Plan of Liquidation. The Debtors are currently in discussions with their stakeholders to develop and file a Plan of Liquidation in the near term.

In re: Orexigen Therapeutics, Inc.

Debtor

   

Case No. 18-10518 (KG)

Reporting Period: August 1, 2018 - August 31, 2018

 

MOR - 1

Consolidated Schedule of Cash Receipts and Disbursements (1)

For the Period: August 1, 2018 - August 31, 2018

(Unaudited)

 

$ USD ‘000s

    August 1, 2018 -
August 31, 2018		     Cumulative
Since Filing		  

Beginning Cash Balance (Book)

    $ 36,874     $ 21,372  

Receipts

     

Operating Receipts

      —         64,422  

Miscellaneous Receipts

      1,487       70,549  
  

 

 

    

 

 

  

Total Receipts

      1,487       134,971  

Operating Disbursements

     

Payroll & Benefits / Contractors

      (554 )      (16,196 ) 

Inventory

      —         (4,406 ) 

Manufacturing and Logistics

      —         (133 ) 

Gross to Net Disbursements

      —         (36,451 ) 

Marketing / Commercial Operations

      (25 )      (15,998 ) 

Ordinary Course Professionals

      —         (637 ) 

Rent / Facilities / Equipment

      (3 )      (559 ) 

Insurance

      —         (279 ) 

IT / Utilities

      (44 )      (341 ) 

Regulatory and Compliance

      (7 )      (562 ) 

Other G&A

      (30 )      (927 ) 
  

 

 

    

 

 

  

Total Operating Disbursements

      (663 )      (76,491 ) 

Operating Cash Flow

      824       58,480  

Reorganization Costs

     

DIP Loan Interest and Fees

      —         (44,480 ) 

US Trustee Fees

      —         (371 ) 

Restructuring Professional Fees

      —         (3,564 ) 
  

 

 

    

 

 

  

Total Reorganization Costs

      —         (48,415 ) 

Total Disbursements

    $ (663 )    $ (124,906 ) 
  

 

 

    

 

 

  

Lender Professional Fees

      (266 )      (1,605 ) 

Net Cash Flow

    $ 558     $ 8,460  

DIP Draw—Cash

      —         7,600  
  

 

 

    

 

 

  

Ending Cash Balance (Book)

    $ 37,432     $ 37,432  

Notes:

 

(1)

The Schedule of Cash Receipts and Disbursements is presented on a book basis.

In re: Orexigen Therapeutics, Inc.

Debtor

   

Case No. 18-10518 (KG)

Reporting Period: August 1, 2018 - August 31, 2018

 

MOR - 1a

Schedule of Disbursements by Debtor Entity (1)

For the Period: August 1, 2018 - August 31, 2018

(Unaudited)

 

$ USD ‘000s
Debtor

    August 1, 2018 - August 31, 2018      Cumulative
Since Filing		  

Orexigen Therapeutics, Inc.

    $ 928      $ 126,511  
  

 

 

     

 

 

  

Total

    $ 928      $ 126,511  

Notes:

 

(1)

The Schedule of Disbursements is presented on a book basis.

In re: Orexigen Therapeutics, Inc.

Debtor

   

Case No. 18-10518 (KG)

Reporting Period: August 1, 2018 - August 31, 2018

 

MOR - 1b

Schedule of Debtor Bank Account Balances (1)

For the Period: August 1, 2018 - August 31, 2018

(Unaudited)

 

$USD ‘000s

Debtor

   

Bank

    Last Four Digits
Account No.		     

Account Description

    Beginning
Balance
8/1/2018		      Ending
Balance
8/31/2018		  

Orexigen Therapeutics, Inc.

    Silicon Valley Bank      6813      General checking    $ —         $ —    

Orexigen Therapeutics, Inc.

    Silicon Valley Bank      1180      Zero-balance lockbox(2)      —          —    

Orexigen Therapeutics, Inc.

    Silicon Valley Bank      3036      Sweep account      36,981        37,483  

Orexigen Therapeutics, Inc.

    Silicon Valley Bank      7307      Utility adequate assurance      10        10  

Orexigen Therapeutics, Inc.

    Silicon Valley Bank      5177      Collateral      100        100  
           

 

 

     

 

 

  

Total Bank Account Balances

             $ 37,091      $ 37,593  
           

 

 

     

 

 

  

Notes:

 

(1)

The Consolidated Schedule of Cash Receipts and Disbursements (MOR-1) and Schedule of Disbursements by Debtor Entity (MOR-1a) represent book balances while MOR-1b represents bank balances. The balances differ primarily due to the bank’s delayed recording of intrabank activity between the general checking and sweep accounts.

(2)

Account was closed in September 2018.

In re: Orexigen Therapeutics, Inc.

Debtor

   

Case No. 18-10518 (KG)

Reporting Period: August 1, 2018 - August 31, 2018

 

MOR - 1c

Schedule of Professional Fees and Expenses Paid

For the Period: August 1, 2018 - August 31, 2018

(Unaudited)

 

                             Month Ended 8/31/18      Cumulative Since Filing  

Payee

   

Category

   

Payor

    Date      Period Covered      Fees      Expenses      Fees      Expenses  

Retained Professionals

                        

Hogan Lovells US LLP

    Debtor Counsel    Orexigen Therapeutics, Inc.         3/12/2018 - 5/31/2018            $ 1,035,364      $ 5,834  

Morris, Nichols, Arsht & Tunnell LLP

    Debtor Local Counsel    Orexigen Therapeutics, Inc.         3/12/2018 - 5/31/2018              342,651        14,812  

Ernst & Young, LLP

    Debtor Financial Advisor    Orexigen Therapeutics, Inc.         3/12/2018 - 5/31/2018              876,132        113,520  

Perella Weinberg Partners

    Debtor Investment Banker    Orexigen Therapeutics, Inc.         3/12/2018 - 5/31/2018              496,713        3,546  

Irell & Manella LLP

    Committee Counsel    Orexigen Therapeutics, Inc.         3/27/2018 - 4/30/2018              326,130        337  

Elliott Greenleaf, P.C.

    Committee Local Counsel    Orexigen Therapeutics, Inc.         3/27/2018 - 4/30/2018              49,332        466  

Kurtzman Carson Consultants LLC

    Claims Agent    Orexigen Therapeutics, Inc.         3/12/2018 - 5/31/2018              143,705        155,188  

Other Restructuring Professionals

                        

Wilmington Trust, National Association

    DIP Administrative Agent    Orexigen Therapeutics, Inc.         3/12/2018 - 7/31/2018            $ 51,600      $ —    

Arnold & Porter Kaye Scholer LLP

    DIP Administrative Agent Counsel    Orexigen Therapeutics, Inc.         3/12/2018 - 7/27/2018              131,889        1,034  

Quinn Emanuel Urquhart & Sullivan, LLP

    DIP Lenders Counsel    Orexigen Therapeutics, Inc.      8/1/2018        3/12/2018 - 8/1/2018        72,639        —          753,286        12,140  

Brown Rudnick LLP

    DIP Lender Counsel    Orexigen Therapeutics, Inc.         2/15/2018 - 5/31/2018              147,048        1,497  

Whiteford Taylor Preston

    DIP Lenders Local Counsel    Orexigen Therapeutics, Inc.         3/12/2018 - 7/27/2018              203,253        2,141  

U.S. Bank, N.A.

    Indenture Trustee    Orexigen Therapeutics, Inc.      8/29/2018        3/1/2018 - 6/30/2018        191,303        1,884        330,948        2,326  

Duane Morris

    DIP Administrative Agent Secondary Counsel    Orexigen Therapeutics, Inc.         4/10/2018 - 7/27/2018              17,609        —    
              

 

 

     

 

 

     

 

 

     

 

 

  

Total

                $ 263,941      $ 1,884        $4,905,659        $312,840  

In re: Orexigen Therapeutics, Inc.

Debtor

   

Case No. 18-10518 (KG)

Reporting Period: August 1, 2018 - August 31, 2018

 

MOR - 2

Statement of Operations

For the Period: August 1, 2018 - August 31, 2018

(Unaudited)

 

$ USD ‘000s

    August 1, 2018 - August 31, 2018     March 12 - August 31, 2018  

Net product sales

    $ —       $ 27,871  

Cost of product sales

      —         (6,336 ) 

Operating expenses:

     

Research and development

      (8 )      (2,674 ) 

Selling, general and administrative

      (74 )      (32,262 ) 

Amortization expense of intangible assets

      —         (2,987 ) 
  

 

 

    

 

 

  

Total operating expenses

      (81 )      (37,924 ) 
  

 

 

    

 

 

  

Loss from operations

      (81 )      (16,389 ) 

Other income/(expense):

     

Interest income

      21       705  

Refundable tax credit(1)

      —         1,300  

Interest expense

      —         (728 ) 
  

 

 

    

 

 

  

Total other income (expenses)

      21       1,276  
  

 

 

    

 

 

  

Net loss

      (60 )      (15,112 ) 

Reorganization expenses(2)

      552       (312,264 ) 
  

 

 

    

 

 

  

Net gain/(loss)

    $ 492     $ (327,377 ) 
  

 

 

    

 

 

  

Notes:

 

(1)

Refundable tax credit includes refundable alternative minimum tax as created by the Tax Cuts and Jobs Act.

(2)

Reorganization expenses include the loss on sale of assets as well as the write up of the notes to the principle balance, the elimination of the debt discount and debt costs related to the 2013 debt. The loss on sale of assets is not final and pending the completion of a valuation of the non-debtor subsidiaries.

In re: Orexigen Therapeutics, Inc.

Debtor

   

Case No. 18-10518 (KG)

Reporting Period: August 1, 2018 - August 31, 2018

 

MOR - 3

Balance Sheet

(Unaudited)

 

     Orexigen Therapeutics, Inc.  

$ USD ‘000s

    As of March 11, 2018      As of August 31, 2018  

Assets

      

Current assets:

      

Cash and cash equivalents

    $ 21,372      $ 37,432  

Accounts receivable, net

      19,203        —    

Inventory

      8,857        —    

Prepaid expenses and other current assets

      6,868        7,994  

Intercompany receivable(1)

      93,353        —    
  

 

 

     

 

 

  

Total current assets

      149,653        45,427  

Non-current assets:

      

Property and equipment, net

      543        —    

Investment in Subsidiary(1)

      19,000        —    

Intangible assets

      66,566        —    

Other long-term assets

      588        1,643  

Restricted cash

      100        110  
  

 

 

     

 

 

  

Total assets

    $ 236,450      $ 47,180  
  

 

 

     

 

 

  

Liabilities and Stockholders’ Equity

      

Current liabilities:

      

Accounts payable (2)

      925        1,787  

DIP loan

      —          —    

Accrued expenses

      3,921        8,148  
  

 

 

     

 

 

  

Total current liabilities:

      4,846        9,934  
  

 

 

     

 

 

  

Total liabilities not subject to compromise

      4,846        9,934  

Total liabilities subject to compromise

      110,381        245,481  

Series Z preferred stock

      3,343        —    

Stockholders’ equity (deficit)

      117,880        (208,235 ) 
  

 

 

     

 

 

  

Total liabilities and stockholders’ equity (deficit)

    $ 236,450      $ 47,180  
  

 

 

     

 

 

  

Notes:

 

(1)

Investment in Subsidiary $19m reclassed from Intercompany Receivable at March 11, 2018 to properly align for reporting.

(2)

Accounts payable excludes all liabilities assumed by the purchaser under the terms of the Asset Purchase Agreement.

In re: Orexigen Therapeutics, Inc.

Debtor

   

Case No. 18-10518 (KG)

Reporting Period: August 1, 2018 - August 31, 2018

 

MOR - 4

Summary of Unpaid Post Petition Accounts Payables

As of August 31, 2018

(Unaudited)

 

$ USD ‘000s

  
                   Number of Days Past Due                

Post Petition Accounts Payable Aging

    Current      0-30      31-60      61-90      Over 90      Total  

Post-Petition Accounts Payable (1)

    $ 146      $ 1,641      $ —        $ —        $ —          1,787  
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  
   $ 146      $ 1,641      $ —        $ —        $ —          1,787  

Notes:

 

(1)

The above figures represent post petition trade payables recorded in the Debtors’ subledger.

In re: Orexigen Therapeutics, Inc.

Debtor

   

Case No. 18-10518 (KG)

Reporting Period: August 1, 2018 - August 31, 2018

 

MOR - 5

Accounts Receivable Aging

As of August 31, 2018

(Unaudited)

 

$ USD ‘000s                                          

Accounts Receivable Aging

    Current      0-30 Days      31-60 Days      61-90 Days      91 Days+      Total  

Accounts Receivable, net

    $ —        $ —        $ —        $ —        $ —        $ —    
  

 

 

     

 

 

     

 

 

     

 

 

     

 

 

     

 

 

  
   $ —        $ —        $ —        $ —        $ —        $ —    

Debtor Questionnaire

 

Must be completed each month

   

Yes

   

No

1.  Have any assets been sold or transferred outside the normal course of business this reporting period? If yes, provide an explanation below.

       X

2.  Have any funds been disbursed from any account other than a debtor in possession account this reporting period? If yes, provide an explanation below.

       X

3.  Have all post petition tax returns been timely filed? If no, provide an explanation below.

    X   

4.  Are workers compensation, general liability and other necessary insurance coverages in effect? If no, provide an explanation below.(1)

    X   

5.  Has any bank account been opened during the reporting period? If yes, provide documentation identifying the opened account(s). If an investment account has been opened provide the required documentation pursuant to the Delaware Local Rule 4001-3.

       X

Notes:

 

(1)

The Debtor received a notice from the Workers’ Compensation Board for the State of New York regarding a failure to maintain disability and paid family leave insurance. This notice is being looked into by the Debtor, but the Debtor believes that all applicable coverages are still in effect.